Bronchial Thermoplasty Improves Ventilation Heterogeneity Measured by Functional Respiratory Imaging in Severe Asthma
DOI: https://doi.org/10.2147/jaa.s454951
2024-04-23
Journal of Asthma and Allergy
Abstract:Chuan T Foo, 1, 2 Graham M Donovan, 3 Francis Thien, 1, 2 David Langton, 2, 4 Peter B Noble 5 1 Department of Respiratory Medicine, Eastern Health, Melbourne, VIC, Australia; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia; 3 Department of Mathematics, University of Auckland, Auckland, New Zealand; 4 Department of Thoracic Medicine, Peninsula Health, Frankston, VIC, Australia; 5 School of Human Sciences, The University of Western Australia, Crawley, WA, Australia Correspondence: Chuan T Foo, Department of Respiratory Medicine, Eastern Health, Melbourne, Victoria, Australia, Tel +613 9095 2414, Email Purpose: Bronchial thermoplasty (BT) is a bronchoscopic intervention for the treatment of severe asthma. Despite demonstrated symptomatic benefit, the underlying mechanisms by which this is achieved remain uncertain. We hypothesize that the effects of BT are driven by improvements in ventilation heterogeneity as assessed using functional respiratory imaging (FRI). Patient and Methods: Eighteen consecutive patients with severe asthma who underwent clinically indicated BT were recruited. Patients were assessed at baseline, 4-week after treatment of the left lung, and 12-month after treatment of the right lung. Data collected included short-acting beta-agonist (SABA) and oral prednisolone (OCS) use, asthma control questionnaire (ACQ-5) and exacerbation history. Patients also underwent lung function tests and chest computed tomography. Ventilation parameters including interquartile distance (IQD; measure of ventilation heterogeneity) were derived using FRI. Results: 12 months after BT, significant improvements were seen in SABA and OCS use, ACQ-5, and number of OCS-requiring exacerbations. Apart from pre-bronchodilator FEV 1 , no other significant changes were observed in lung function. Ventilation heterogeneity significantly improved after treatment of the left lung (0.18 ± 0.04 vs 0.20 ± 0.04, p=0.045), with treatment effect persisting up to 12 months later (0.18 ± 0.05 vs 0.20 ± 0.04, p=0.028). Ventilation heterogeneity also improved after treatment of the right lung, although this did not reach statistical significance (0.18 ± 0.05 vs 0.19 ± 0.04, p=0.06). Conclusion: Clinical benefits after BT are accompanied by improvements in ventilation heterogeneity, advancing our understanding of its mechanism of action. Beyond BT, FRI has the potential to be expanded into other clinical applications. Keywords: asthma, computed tomography, computational fluid dynamics, imaging, mechanism of action, pathophysiology Asthma is a common disease that is estimated to affect 250 million people worldwide and accounts for >20 million disability-adjusted life years. 1 Asthma is characterized clinically by variable symptoms of cough, chest tightness and shortness of breath; physiologically by evidence of reversible airflow limitation; and pathologically by increased thickness of the airway smooth muscle (ASM) layer among other structural changes. 2 The majority of patients with asthma can be successfully managed with inhaled corticosteroids (ICS) and bronchodilators, and by addressing comorbidities. However, about 10% experience uncontrolled symptoms and frequent exacerbations despite optimal therapy, 3 and are defined as having severe asthma. 4 Whilst biologics and macrolides have roles in managing these patients, 5 bronchial thermoplasty (BT) offers another modality with different mechanisms of action. BT involves the direct application of radiofrequency energy to the mucosa of airways 2–10mm in diameter, resulting in thermal ablation and shrinking of the underlying ASM. 6–8 BT has been shown in randomized controlled trials to improve asthma symptoms, reduce asthma exacerbations, and improve quality of life, 9–12 with benefits persisting up to 10 years after treatment. 13–15 Despite this, the physiological changes that underpin the clinical benefits remain poorly understood, especially given the small fraction of airways treated, with spirometry showing little or no change. 9–11,15,16 Mathematical modelling of the physiological behavior of the asthmatic lung suggests that the dilation of the airways treated during BT should lead to a reopening cascade in the smaller distal untreated airways, and a redistribution of airflow that improves ventilation heterogeneity. 17 Indeed, there is now emerging evidence that these proposed changes do occur in patients after BT. For instance, imaging studies have demonstrated that airway luminal volume increases, 18–21</su -Abstract Truncated-
immunology,allergy,respiratory system